
    
      This is a randomized, double-blind, placebo-controlled, study in up 24 participants and will
      be conducted concurrently in 2 parts (Part A and Part B); participants will be allocated into
      Part A or Part B according to type of HAE (i.e., either HAE-1/HAE-2 in Part A or HAE-nC1-INH
      in Part B). Part A will be randomized, double-blind, and placebo-controlled; and Part B will
      be open-label. The length of participation in the study will be approximately 8 months, which
      includes an up to 8-week screening period, a 12-week treatment period, and a 13-week
      post-treatment period.
    
  